Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 6/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16055815 | 1.00 | ALDH1A1 (0.69) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL10325767 | 1.00 | ALDH1A1 (0.69) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL8320309 | 0.92 | ALDH1A1 (0.62) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3948461 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3948456 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL381922 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL28135182 | 0.87 | ALDH1A1 (0.83) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL28640121 | 0.85 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL28640119 | 0.85 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL12879965 | 0.85 | ALDH1A1 (0.74) | ALDH1A1GAATSHREPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239154-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-5925624-A | ANTIINFLAMMATORY AGENTS TREATING PATIENTS WITH INFLAMMATORY CONDITIONS SUSCEPTIBLE TO LEUKOCYTE-INDUCED TISSUE DAMAGE | GLAXO GROUP LIMITED (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0680488-B1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LTD (GB) | 1998-04-08 | — | — | EP | disclosed |
| EP-0680488-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017090-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 4076/4885GAA 2969/4885TSHR 3940/4885 |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 4076/4885GAA 2969/4885TSHR 3940/4885 |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 4076/4885GAA 2969/4885TSHR 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.